Guardian Pharmacy Services, Inc.
GRDN NYSE· Retail-Drug Stores And Proprietary Stores
Last close · Oct 27, 2026
$39.56
KIRA · Stoqly’s AI analyst, in plain words
- Guardian Pharmacy Services, Inc. had $1.4B of revenue in fiscal 2025, up 17.9% on the year before.
- Its operating margin was 5.0%, up 10.1 pts: of every 100 in sales, about 5 is left after running the business.
- Guardian Pharmacy Services, Inc. made $49.2M of net profit in fiscal 2025.
- Free cash flow was $86.8M in fiscal 2025, 6.0% of revenue.
- Guardian Pharmacy Services, Inc. has $65.6M more cash than debt.
Market cap
—
P/E
—
Revenue
$1.4B
Net income
$49.2M
Free cash flow
$86.8M
Operating margin
5.0%
Guardian Pharmacy Services, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+17.9%
Yes. Sales grew 17.9% last year.
Does it make a profit?
3.4%
A little. It keeps 3.4% of every sale as profit.
Does profit turn into cash?
6.0%
Partly. 6.0% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
What Guardian Pharmacy Services, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Legal name
- Guardian Pharmacy Services, Inc.
- CIK
- 0001802255
Guardian Pharmacy Services, Inc. · GRDN
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Revenue | $1.2B | $1.4B |
| Revenue growth | — | 17.9% |
| Gross margin | 19.9% | 20.2% |
| Operating margin | −5.1% | 5.0% |
| Net income | −$110M | $49.2M |
| Net margin | −9.0% | 3.4% |
| Cash | ||
| Cash from operations | $58.0M | $100M |
| Capital expenditure | $14.7M | $13.4M |
| Free cash flow | $43.3M | $86.8M |
| FCF margin | 3.5% | 6.0% |
| Debt and strength | ||
| Cash and short-term investments | $4.7M | $65.6M |
| Debt incl. finance leases | $0.0M | $0.0M |
| Shareholders' equity | $150M | $218M |
| Net debt / EBITDA | — | −0.7x |
| Current ratio | 1.1x | 1.4x |
| Interest coverage | −19.2x | 109.3x |
| Returns and quality | ||
| Return on capital | −34.2% | 31.8% |
| Return on equity | −73.4% | 26.8% |
| Return on tangible equity | −167.3% | 41.1% |
| Piotroski F-score | — | 6 |
| Altman Z'' | −0.1 | 3.9 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$419M
9 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Guardian Pharmacy Services, Inc. · GRDN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $39.56 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001802255). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.